Zymeworks: Difference between revisions
No edit summary |
No edit summary |
||
| Line 36: | Line 36: | ||
'''Zymeworks''' Inc. is a privately held biotechnology company based in [[Vancouver]], |
'''Zymeworks''' Inc. is a privately held biotechnology company based in [[Vancouver]], |
||
[[British Columbia]] that develops protein therapeutics for the treatment of [[cancer]] as well as for [[Autoimmunity|autoimmune]] and [[Inflammation|inflammatory diseases]]. The products are based upon the company's [[molecular modeling]] software for optimizing protein structure.<ref>(April 12, 2012). "[http://zymeworks.com/about/index.html About Zymeworks]". Retrieved 2012-04-12.</ref><ref>{{cite journal|last=Holmes|first=David|title=Buy Buy Bispecific Antibodies|journal=Nature Reviews Drug Discovery|year=2011|volume=10|pages=798|doi=10.1038/nrd3581}}</ref><ref>{{cite journal|last=DePalma|first=Angelo|title=Improving Classic Antibody Engineering: Diverse Methodologies and Fresh Insights Turn a Good Technique into an Even Better One|journal=Genetic Engineering and Biotechnology News|year=2011|volume=31|issue=36}}</ref> In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech |
[[British Columbia]] that develops protein therapeutics for the treatment of [[cancer]] as well as for [[Autoimmunity|autoimmune]] and [[Inflammation|inflammatory diseases]]. The products are based upon the company's [[molecular modeling]] software for optimizing protein structure.<ref>(April 12, 2012). "[http://zymeworks.com/about/index.html About Zymeworks]". Retrieved 2012-04-12.</ref><ref>{{cite journal|last=Holmes|first=David|title=Buy Buy Bispecific Antibodies|journal=Nature Reviews Drug Discovery|year=2011|volume=10|pages=798|doi=10.1038/nrd3581}}</ref><ref>{{cite journal|last=DePalma|first=Angelo|title=Improving Classic Antibody Engineering: Diverse Methodologies and Fresh Insights Turn a Good Technique into an Even Better One|journal=Genetic Engineering and Biotechnology News|year=2011|volume=31|issue=36}}</ref> In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. <ref name="HT">{{cite web | url= http://www.hottopics.ht/stories/lists/10-healthtech-companies-raised-capital-2014 | title=The 10 healthtech companies that raised the most capital in 2014 | publisher=Hot Topics | date=January 2015 | accessdate=14 January 2015}}</ref> |
||
==Azymetric™== |
==Azymetric™== |
||
Revision as of 13:51, 14 January 2015
 | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | , |
Key people | Ali Tehrani Donald L. Drakeman |
| Products | Pharmaceuticals |
Number of employees | 36 (17 PhDs) |
| Website | www.zymeworks.com |
Zymeworks Inc. is a privately held biotechnology company based in Vancouver, British Columbia that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure.[1][2][3] In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. [4]
Azymetric™
This is an IgG1-based heterodimeric antibody scaffold that consists of two different heavy chains engineered to exclusively assemble into a single molecule, allowing bi-specific binding to two different antigens or drug targets. The Azymetric™ scaffold is engineered by making amino acid changes in the CH3 region of the constant Fc domain of the IgG1.[5][6] This scaffold can also be engineered with tailored effector function and optimized serum half-life. Bi-specific antibody therapeutics potentially allow drug-makers to combine two existing drugs used as a cocktail into one potent therapeutic.
Awards & Recognition
- 12th Place, BC's Leading Innovators, 2011[7]
- Life Science Emerging Rocket, 2009, 2010, 2011[8]
- Early stage Company of the year – Industrial & Agriculture, BIOTECanada Gold Leaf Awards, 2009[9]
References
- ^ (April 12, 2012). "About Zymeworks". Retrieved 2012-04-12.
- ^ Holmes, David (2011). "Buy Buy Bispecific Antibodies". Nature Reviews Drug Discovery. 10: 798. doi:10.1038/nrd3581.
- ^ DePalma, Angelo (2011). "Improving Classic Antibody Engineering: Diverse Methodologies and Fresh Insights Turn a Good Technique into an Even Better One". Genetic Engineering and Biotechnology News. 31 (36).
- ^ "The 10 healthtech companies that raised the most capital in 2014". Hot Topics. January 2015. Retrieved 14 January 2015.
- ^ (April 19, 2012). "Azymetric". Retrieved 2012-04-19. https://www.landesbioscience.com/journals/mabs/article/25632/
- ^ https://www.landesbioscience.com/journals/mabs/article/25632/
- ^ (April 4, 2011). "Congratulations to Zymeworks, #12 in 2011's Most Innovative Companies in B.C.". Retrieved 2012-04-12.
- ^ (March 1, 2011) "2011 Ready to Rocket Life Science Presentation" Retrieved 2012-04-12.
- ^ "2009 BIOTECanada Annual Report". Retrieved 2012-04-12.
 | This article about a Canadian corporation or company is a stub. You can help Wikipedia by expanding it. |